Strategy+ is advising one of the world’s premier biopharmaceutical companies Pfizer (NYSE: PFE) on the acquisition of Medivation, Inc. (NASDAQ:MDVN), a biopharmaceutical company focused on developing and commercializing small molecules for oncology. The definitive merger agreement was announced August 22, 2016. Pfizer has agreed to acquire Medivation for a total enterprise value of approximately $14 Billion.
Note to Editors: This press release may contain forward-looking statements regarding Strategy+’s intentions and interests. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied in these statements. The firm does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
